The partnership will see compounds from the retinal disease pipeline portfolio of Boehringer Ingelheim combined with the intravitreal (IVT) drug delivery technologies of Inflammasome. Inflammasome’s technology will be
LINZESS was approved by the National Medical Products Administration for adults with IBS-C in China in January 2019. LINZESS is expected to be launched in China in the
The PREVENT trial is assessing the efficacy and safety of Cosentyx compared to placebo with the primary endpoint being ASAS40 at Week 16. All the secondary endpoints of
Topline data from this dose regimen trial is expected in the first half of 2020. “We are extremely grateful to the patients who volunteer to participate in our
The primary endpoint is the change from baseline in the 6-minute walk test (6-MWT) at 12 months. Secondary endpoints will evaluate the efficacy of patisiran on quality of
The fast track designation is for the use of Farxiga in reducing the chances of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart
The Allergenic Products Advisory Committee (APAC) voted seven to two that the efficacy data and eight to one that the safety data, along with other safeguards, are enough
The data demonstrate that, in two Phase I single-dose clinical studies in healthy volunteers, ARO-APOC3 reduced plasma Apolipoprotein C-III (apoC-III) and ARO-ANG3 reduced plasma angiopoietin like protein 3
The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response
As part of the collaboration, VBI plans to add an additional study arm to Part B of the company’s ongoing, multi-center, open-label Phase 1/2a clinical study targeting recurrent
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.